Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Feb 1;97(3):826–832. doi: 10.1172/JCI118482

Patient selection may affect gene therapy success. Dominant negative effects observed for ornithine transcarbamylase in mouse and human hepatocytes.

M A Morsy 1, J Z Zhao 1, T T Ngo 1, A W Warman 1, W E O'Brien 1, F L Graham 1, C T Caskey 1
PMCID: PMC507121  PMID: 8609240

Abstract

We have achieved significant improvement of ornithine transcarbamylase deficiency (OTCD) in a mouse model through adenoviral-mediated gene transfer of the human ornithine transcarbamylase cDNA. Substantial reduction in orotic aciduria was observed within 24 h of treatment. Metabolic correction was later associated with phenotypic correction and moderate increase in enzymatic activity. In an effort to identify the level of gene expression required to achieve wild-type levels of enzyme activity we uncovered a dominant negative effect of the endogenous mutant protein on the activity of the delivered recombinant wild-type protein. This phenomenon is relevant to homomultimeric protein defects such as OTCD, represent a challenging category of disorders for gene therapy. Thus, although our findings indicate that adenoviral-mediated gene transfer may have potential as a short-term treatment for OTCD in humans and may be effective especially during catabolic crisis, the observations in this study suggest that careful patient selection based on mutation class may be essential for initial OTCD gene therapy trials, and perhaps, for other homomultimeric enzyme deficiencies being considered as gene therapy targets.

Full Text

The Full Text of this article is available as a PDF (286.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arn P. H., Hauser E. R., Thomas G. H., Herman G., Hess D., Brusilow S. W. Hyperammonemia in women with a mutation at the ornithine carbamoyltransferase locus. A cause of postpartum coma. N Engl J Med. 1990 Jun 7;322(23):1652–1655. doi: 10.1056/NEJM199006073222307. [DOI] [PubMed] [Google Scholar]
  2. Batshaw M. L., Msall M., Beaudet A. L., Trojak J. Risk of serious illness in heterozygotes for ornithine transcarbamylase deficiency. J Pediatr. 1986 Feb;108(2):236–241. doi: 10.1016/s0022-3476(86)80989-1. [DOI] [PubMed] [Google Scholar]
  3. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  4. Briand P., Cathelineau L., Kamoun P., Gigot D., Penninckx M. Increase of ornithine transcarbamylase protein in sparse-fur mice with ornithine transcarbamylase deficiency. FEBS Lett. 1981 Jul 20;130(1):65–68. doi: 10.1016/0014-5793(81)80666-7. [DOI] [PubMed] [Google Scholar]
  5. DeMars R., LeVan S. L., Trend B. L., Russell L. B. Abnormal ornithine carbamoyltransferase in mice having the sparse-fur mutation. Proc Natl Acad Sci U S A. 1976 May;73(5):1693–1697. doi: 10.1073/pnas.73.5.1693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Doolittle D. P., Hulbert L. L., Cordy C. A new allele of the sparse fur gene in the mouse. J Hered. 1974 May-Jun;65(3):194–195. doi: 10.1093/oxfordjournals.jhered.a108500. [DOI] [PubMed] [Google Scholar]
  7. Finkelstein J. E., Francomano C. A., Brusilow S. W., Traystman M. D. Use of denaturing gradient gel electrophoresis for detection of mutation and prospective diagnosis in late onset ornithine transcarbamylase deficiency. Genomics. 1990 Jun;7(2):167–172. doi: 10.1016/0888-7543(90)90537-5. [DOI] [PubMed] [Google Scholar]
  8. Goldstein R. M., Klintmalm G. K., Husberg B. S., Gonwa T. A., Polter D. Liver transplantation: a review of the first 200 patients. Transplant Proc. 1991 Apr;23(2):1780–1781. [PubMed] [Google Scholar]
  9. Graham F. L., Smiley J., Russell W. C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977 Jul;36(1):59–74. doi: 10.1099/0022-1317-36-1-59. [DOI] [PubMed] [Google Scholar]
  10. Grompe M., Jones S. N., Loulseged H., Caskey C. T. Retroviral-mediated gene transfer of human ornithine transcarbamylase into primary hepatocytes of spf and spf-ash mice. Hum Gene Ther. 1992 Feb;3(1):35–44. doi: 10.1089/hum.1992.3.1-35. [DOI] [PubMed] [Google Scholar]
  11. Gruppuso P. A., Boylan J. M. Developmental changes in the activity and cellular localization of hepatic casein kinase II in the rat. J Cell Biochem. 1995 May;58(1):65–72. doi: 10.1002/jcb.240580109. [DOI] [PubMed] [Google Scholar]
  12. Hodges P. E., Rosenberg L. E. The spfash mouse: a missense mutation in the ornithine transcarbamylase gene also causes aberrant mRNA splicing. Proc Natl Acad Sci U S A. 1989 Jun;86(11):4142–4146. doi: 10.1073/pnas.86.11.4142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jones S. N., Grompe M., Munir M. I., Veres G., Craigen W. J., Caskey C. T. Ectopic correction of ornithine transcarbamylase deficiency in sparse fur mice. J Biol Chem. 1990 Aug 25;265(24):14684–14690. [PubMed] [Google Scholar]
  14. Largillière C., Houssin D., Gottrand F., Mathey C., Checoury A., Alagille D., Farriaux J. P. Liver transplantation for ornithine transcarbamylase deficiency in a girl. J Pediatr. 1989 Sep;115(3):415–417. doi: 10.1016/s0022-3476(89)80843-1. [DOI] [PubMed] [Google Scholar]
  15. Maestri N. E., Hauser E. R., Bartholomew D., Brusilow S. W. Prospective treatment of urea cycle disorders. J Pediatr. 1991 Dec;119(6):923–928. doi: 10.1016/s0022-3476(05)83044-6. [DOI] [PubMed] [Google Scholar]
  16. Matsuda I., Nagata N., Matsuura T., Oyanagi K., Tada K., Narisawa K., Kitagawa T., Sakiyama T., Yamashita F., Yoshino M. Retrospective survey of urea cycle disorders: Part 1. Clinical and laboratory observations of thirty-two Japanese male patients with ornithine transcarbamylase deficiency. Am J Med Genet. 1991 Jan;38(1):85–89. doi: 10.1002/ajmg.1320380119. [DOI] [PubMed] [Google Scholar]
  17. Morsy M. A., Alford E. L., Bett A., Graham F. L., Caskey C. T. Efficient adenoviral-mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes. J Clin Invest. 1993 Sep;92(3):1580–1586. doi: 10.1172/JCI116739. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Qureshi I. A., Letarte J., Ouellet R. Ornithine transcarbamylase deficiency in mutant mice I. Studies on the characterization of enzyme defect and suitability as animal model of human disease. Pediatr Res. 1979 Jul;13(7):807–811. doi: 10.1203/00006450-197907000-00003. [DOI] [PubMed] [Google Scholar]
  19. Rowe P. C., Newman S. L., Brusilow S. W. Natural history of symptomatic partial ornithine transcarbamylase deficiency. N Engl J Med. 1986 Feb 27;314(9):541–547. doi: 10.1056/NEJM198602273140903. [DOI] [PubMed] [Google Scholar]
  20. Stajner A., Sůva J., Musil F. The determination of orotic acid in the blood serum by means of the spectrophotometric method. Experientia. 1968 Feb 15;24(2):116–117. doi: 10.1007/BF02146929. [DOI] [PubMed] [Google Scholar]
  21. Stratford-Perricaudet L. D., Levrero M., Chasse J. F., Perricaudet M., Briand P. Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther. 1990 Fall;1(3):241–256. doi: 10.1089/hum.1990.1.3-241. [DOI] [PubMed] [Google Scholar]
  22. Volź K. W., Krause K. L., Lipscomb W. N. The binding of N-(phosphonacetyl)-L-aspartate to aspartate carbamoyltransferase of Escherichia coli. Biochem Biophys Res Commun. 1986 Apr 29;136(2):822–826. doi: 10.1016/0006-291x(86)90514-0. [DOI] [PubMed] [Google Scholar]
  23. Wente S. R., Schachman H. K. Shared active sites in oligomeric enzymes: model studies with defective mutants of aspartate transcarbamoylase produced by site-directed mutagenesis. Proc Natl Acad Sci U S A. 1987 Jan;84(1):31–35. doi: 10.1073/pnas.84.1.31. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES